Authors' reply to the comment by Patel J, Martin JH and Lucas CJ

M Hopp¹, B Bosse¹

Affiliations

Comment

M Hopp et al. Eur J Pain. 2018 Jan.

. 2018 Jan;22(1):203-204.

doi: 10.1002/ejp.1142.

M Hopp¹, B Bosse¹

No abstract available

Comment on

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M. Dupoiron D, et al. Eur J Pain. 2017 Oct;21(9):1528-1537. doi: 10.1002/ejp.1054. Epub 2017 Jun 22. Eur J Pain. 2017. PMID: 28641363 Free PMC article. Clinical Trial.
Comment on a paper by Dupoiron et al. "A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone- naloxone (up to 160/80 mg daily) versus oxycodone PR".
Patel J, Martin JH, Lucas CJ. Patel J, et al. Eur J Pain. 2017 Nov;21(10):1772-1773. doi: 10.1002/ejp.1098. Eur J Pain. 2017. PMID: 28990731 No abstract available.